Greater Philadelphia – Regional Life Sciences Roundup – October 29, 2026
Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
A few weeks ago, Big Pharma was paying billions for molecules that hadn’t been tested in a single patient. This week in Greater Philadelphia, the money came with receipts. Across the send, companies earned their next step by showing their work first: hitting the targets a lender set, putting out early data alongside a raise, clearing a patent hurdle, and winning a regulatory designation that speeds up review without promising approval.
West Chester’s Verrica Pharmaceuticals hit the growth milestones tied to its loan, unlocking the full $27.5 million credit facility to grow its approved product and finish late-stage trials. Wayne’s Aclaris Therapeutics priced a $50 million offering alongside early data for ATI-052, an antibody that works on two inflammation targets at once.
Teleflex earned FDA Breakthrough Device Designation for FreeSolve, a heart scaffold that supports an artery while it heals and then dissolves. The device is still being studied in the U.S. Malvern’s Maxona Pharmaceuticals won a patent allowance for using nefopam against chronic itch with no known cause, and added MAX-425 to its pipeline for the same problem.
Even the week’s biggest deal fits the pattern. Cencora agreed to acquire American Oncology Network for $2.4 billion, deepening a relationship that has been building for years.
Financial
Tracking the capital moving through Greater Philadelphia— funding rounds, M&A activity, and investment trends shaping Philadelphia, Southern New Jersey, and Delaware’s life sciences companies.
A West Chester Biotech Just Cleared the Bar to Unlock More Financing
A West Chester dermatology company has hit the growth goals it set when it secured a loan earlier this year, giving it access to the full amount of that financing. The debt doesn’t dilute existing shareholders, and the company says the money will go toward growing its approved product and finishing late-stage trials in a new skin condition. Here’s what the company says it achieved and what the financing is meant to support. Read More >
Early Signals, New Capital: A Dual-Target Antibody Takes Its Next Step
A Wayne biotech has raised new funding on the same day it shared early data on an experimental antibody that works on two inflammation targets at once. The results come from two small studies in patients with a skin condition and asthma, and they set the stage for the company’s next trial in a chronic allergic condition of the esophagus. Here’s what the early data showed and where the company plans to go from here. Read More >
How a Child’s Simple Idea Became a Major Force in Childhood Cancer Research
What started as a child’s front-yard lemonade stand has grown into a movement that just passed a major fundraising milestone for childhood cancer research. The organization behind it says the money has gone toward research, clinical trials, and support for families, and it credits supporters of every age for getting there. Here’s how the story began and what the organization says the funding has helped make possible. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
From Sequencing to Cell Therapy: A Leader With Both Joins an Exton Company
Yuxiang (Richard) Huang, Ph.D., has joined Exton-based Frontage Laboratories as Vice President of Biologics, Gene and Cell Therapy and Genomics Services. He brings more than 20 years of experience across genomics, advanced therapeutics, and process development, including work on cell and gene therapy projects moving toward clinical and commercial manufacturing. Here’s a look at his path and what the company says he’ll bring to its growing services. Read More >
A Revenue Leader Joins a Philadelphia Company Built to Help Drugmakers Get Paid
Chris Hare has joined Philadelphia-based IntegriChain as Chief Revenue Officer, where he’ll lead the company’s commercial strategy. He brings more than two decades of experience building and scaling revenue teams in healthcare and healthcare software, and the appointment comes as the company marks a milestone anniversary and plans for growth next year. Here’s what the company says made him the right fit. Read More >
A Global Tech Leader Steps Into a Key Role at a Company That Supplies Science
Mikey Santiago has joined Radnor-based Avantor as Chief Information Officer, where he’ll lead the company’s global technology strategy and digital transformation. He comes from senior technology roles at large life sciences and diagnostics organizations and brings experience with major integrations, modernization, and AI. Here’s what the company says made him the right fit as it looks to the future. Read More >
Honoring the Work That Put Genetics at the Center of Breast Cancer Care
The Basser Center for BRCA at Penn’s Abramson Cancer Center has named Judy Garber, MD, MPH, of Dana-Farber Cancer Institute as the recipient of its 2026 Global Prize. She’s recognized for decades of work in cancer genetics, from how care is delivered to people with inherited BRCA mutations to the treatments those patients receive today. Here’s what the center says set her contributions apart. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Philadelphia, New Jersey, and Delaware life sciences and biotech employers.
The Life Sciences Services Firm Built Around Who Shows Up
A year after launching, a Doylestown firm says it’s built around one simple promise for life sciences companies: the people you meet at the start are the people who do the work. The company handles the specialized work that keeps regulated labs and manufacturing sites running, and it says it scopes each project to what the client actually needs instead of a standard package. Here’s how it describes its first year and what it’s planning next. Read More >
A New Navy Yard Training Center Is Teaching the Skills Behind Making Medicine
A new training center has opened at the Philadelphia Navy Yard with a clear goal: preparing people for hands-on careers in making pharmaceuticals and advanced therapies. The short program blends classroom instruction, simulations, and practice, and it welcomes participants from a range of educational backgrounds. Here’s how it works and who it’s built for. Read More >
Working on the Next Big Countermeasure? Time to Apply Is Almost Up
A biodefense-focused accelerator is offering non-dilutive funding to early-stage companies and university teams working on certain countermeasures to health threats. Awards support short, milestone-based projects, with mentoring and access to government subject matter experts. Applications are closing this week, so here’s what it’s looking for and who should consider applying. Read More >
Who’s hiring?!
Top feature employer (linked), a couple of lines on who they are, their goals, how they view talent/hiring/ no. of open roles (specific region), followed by CTA
Other employers and available roles we’re paying attention to this week:
Top Employer
Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical has grown from a small startup into a leading global musculoskeletal technology company, with over 6,000 employees and a presence in 65 countries. The company designs, develops, and manufactures instruments and implants for spine surgery, orthopedic trauma, joint reconstruction, and regenerative biologics.
With a strong emphasis on providing exceptional response, innovation, advancing patient care, Globus Medical extends that mission through its Musculoskeletal Education and Research Center, partnering with surgeons and hospitals on training and clinical research. Globus Medical is a major driver of medtech talent right here in the Greater Philadelphia region, with roles spanning engineering, manufacturing, clinical development, quality and compliance, and commercial operations.
They are currently hiring across 170+ roles in the Greater Philadelphia region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- RhyGaze (Philadelphia, PA) is hiring an (Associate) Director, CMC Analytical Development | Apply Now >
- Parexel (Pennsylvania) is Manager, Production Services | Apply Now >
- Neuronnetics (Malvern, PA) is hiring a Senior Customer Operations Specialist | Apply Now >
- Madrigal Pharmaceuticals (Conshohocken, PA) is hiring an Associate Director, Market Access Analytics | Apply Now >
- Johnson & Johnson (West Chester, PA) is hiring a Senior Manufacturing Engineer-Orthopaedic | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across Greater Philadelphia.
A Conshohocken Giant Makes a Big Move in Community Cancer Care
A Conshohocken healthcare giant has agreed to buy a national network of community oncology practices, deepening a relationship that has been building for years. The deal would expand the buyer’s physician-led oncology business into more states, and both sides say doctors would keep control of clinical decisions. Here’s what the companies say the deal is meant to do and what still has to happen before it closes. Read More >
After Surgery, Then What? A Philadelphia Biotech Tests a Way to Keep Liver Cancer From Coming Back
A Philadelphia immunotherapy company has started a Phase 2 trial in people with high-risk liver cancer after surgery, a group a trial investigator says has no approved options to prevent recurrence. The experimental treatment is personalized, built from the mutations found in each patient’s own tumor, with the goal of training the immune system to go after the cancer. The company is also adding a new chief medical officer to lead the trial and its pipeline. Here’s how the approach works and what the study will look at. Read More >
What If an Artery Support Didn’t Have to Stay Forever?
A Wayne medtech company has received a regulatory designation for a heart scaffold that supports an artery while it heals and then dissolves, an alternative to leaving a permanent implant behind. The designation is meant to speed up how the FDA reviews devices that address unmet needs, but it isn’t an approval, and the device is still being studied in the U.S. Here’s what the device is designed to do and what comes next. Read More >
Ecosystem
The partnerships, programs, and policy moves building Greater Philadelphia’s life sciences infrastructure — and the organizations driving it forward.
Two Drug Developers, One Mutation, and a New Idea for Colorectal Cancer
Two drug developers are teaming up to test a three-part combination in people newly diagnosed with advanced colorectal cancer driven by a specific common mutation. One brings a pill that targets the mutated protein, the other an antibody that goes after the cancer cells in a different way, and both would be paired with standard chemotherapy. Here’s what the early-stage study aims to find out and why the companies think the pairing is worth testing. Read More >
Two Moves on One Mystery Condition from a Malvern Biotech
A Malvern drug developer has taken two steps in a condition that gets little attention: itching that lingers for weeks with no identifiable cause. The company has cleared a key patent hurdle for using its lead compound against itch, and it’s adding a new preclinical candidate aimed at the same problem. Here’s what the company says the opportunity is and what still has to happen before any treatment could reach patients. Read More >
What Pennsylvania’s Newest Research Law Means for Labs and Beyond
A new Pennsylvania law is changing the rules for research facilities that use dogs and cats, from what happens to the animals once a study ends to the conditions attached to state-funded work. It also touches the cosmetics business. Here’s what the new requirements say, who they affect, and when they take effect. Read More >
The Overlooked Barrier in Clinical Trials Is Just Getting There
For many people in clinical trials, one of the hardest parts isn’t the treatment but getting to the appointments. A Conshohocken clinical trial technology company has expanded its travel service for participants, adding ride options and a choice of how much hands-on help sponsors offer. Here’s what’s new and who the company says it’s meant to help. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in PHL biotech and life sciences this week.
How Emerging Biotechs Use FDA INTERACT Meetings to Avoid Costly Missteps
For small biotech teams, some of the costliest regulatory mistakes come from questions asked too late. This guide walks through an early FDA meeting designed to give emerging companies targeted feedback before they commit to expensive studies and manufacturing plans. It covers when the meeting makes sense, how to frame a request, and why some requests don’t get approved. Read More >
Out of the Lab: Operationalizing Cell and Gene Therapy Eytan Abraham
A manufacturing leader in cell and gene therapy explains why the next wave of treatments, ones made inside the patient instead of outside the body, will need a very different operational playbook. He walks through where cost and yield get lost, why early choices lock in a therapy’s price, and what founders should ask before picking a manufacturing partner. Here’s why he says the end game has to be designed before the first trial begins. Listen Now >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across Greater Philadelphia’s life sciences ecosystem that you don’t want to miss.
Open House @LSPA
Thursday, November 5, 2026 • 8:30–10 AM • King of Prussia, PA
Hosted by Life Sciences PA | Register Now >
Philadelphia Drug Discovery Forum
Wednesday, November 11, 2026 • 4–6 PM • Philadelphia, PA
Hosted by The Wistar Institute | Register Now >
Patient Summit
Thursday, November 12, 2026 • 8–1:30 PM • Philadelphia, PA
Hosted by Life Sciences PA | Register Now >
Did we miss something!? Drop us a line →
Stay connected to Greater Philadelphia’s life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the Greater Philadelphia Region Roundup every Thursday.
The week’s most important life sciences news from PHL— delivered to your inbox.
